Allelica’s platform is a giant step forward in the delivery of precision medicine for all
Valor Ventures Fund 2 is pleased to announce its seventh investment, a $1.75 million Series Seed financing of Allelica, Inc. Valor General Partner Gary Peat joins the Allelica board of directors. In addition to lead investor Valor Ventures, participants in the round included AI-focused venture fund Pi Campus and prestigious genetics research institution Medical Genetics Center (MGZ) in Munich as a strategic investor.
Says Peat, “Allelica brings precision medicine into mainstream clinical practice through a Software-as-a-Service platform for the prediction of complex, genetic diseases using proprietary polygenic risk scores. With major customers across three continents, Allelica is poised to be the first mass adoption of precision medicine. For example, in cardiology, Allelica has partnered with a leader in therapies for Coronary Artery Disease, Merck, to develop data-driven cardiovascular disease-risk stratification tools based upon Allelica’s polygenic risk scores for Coronary Artery Disease.”
Allelica’s co-founders include two of the world’s leading genomic bioinformaticians and Polygenic Risk Score (PRS) scientists, CEO Giordano Bottà, Ph.D. and Chief Science Officer, George Busby, Ph.D., plus data scientist Paolo Di Domenico, Ph.D. Their fundamental research contributions helped develop the algorithms and AI that make genomic analysis possible at scale. With this round, Allelica has hired a Baltimore-based sales leader, Edgar Carter, as VP of Sales.
Bottà says, “The Valor team brings decades of experience investing at seed stage in healthcare information technology and informatics in Allelica’s largest market, North America.”
